Abstract
Purpose
To investigate whether radiotherapy for prostate cancer increases the risk of therapy-related rectal cancer and colon cancer.
Methods
A systematic literature search was carried out using the Medline (PubMed), EMBASE, and the Cochrane Library to identify studies examining the association between radiotherapy for prostate cancer and secondary colorectal cancer (rectal cancer and colon cancer) published before March 19, 2018. The risk of second colorectal cancer after radiotherapy was summarized using unadjusted odds ratio (OR) and adjusted hazard ratio (HR) with their 95% confidence interval (CI). Subgroup and sensitivity analyses were conducted to detect potential bias and heterogeneity.
Results
After study selection, 16 reports were retrieved for analysis. When patients received radiotherapy compared with those unexposed to radiation, there was an increased risk of the rectal cancer (OR 1.37, 95%CI 1.01 to 1.85), but not colon cancer. According to adjusted HR, there was an increased risk of the rectal cancer (HR 1.64, 95%CI 1.39 to 1.94), and colon cancer (HR 1.33, 95%CI 1.02 to 1.76). The OR for rectal cancer showed an increased risk with longer latent period (5 years lag time versus 10 years lag time, OR: 1.56 versus 2.22). Brachytherapy had no association with second cancer across all analyses.
Conclusions
Radiotherapy was associated with an increased risk of subsequent rectal cancer compared with patients unexposed to radiation. Colon may be free from the damage of radiation. Brachytherapy had no association with second rectal cancer or colon cancer.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00384-018-3114-7/MediaObjects/384_2018_3114_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00384-018-3114-7/MediaObjects/384_2018_3114_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00384-018-3114-7/MediaObjects/384_2018_3114_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00384-018-3114-7/MediaObjects/384_2018_3114_Fig4_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00384-018-3114-7/MediaObjects/384_2018_3114_Fig5_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00384-018-3114-7/MediaObjects/384_2018_3114_Fig6_HTML.png)
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442
Liu S, Yang L, Yuan Y, Li H, Tian J, Lu S, Wang N, Ji J (2018) Cancer incidence in Bei**g, 2014. Chin J Cancer Res 30(1):13–20. https://doi.org/10.21147/j.issn.1000-9604.2018.01.02
Shuryak I, Sachs RK, Brenner DJ (2010) Cancer risks after radiation exposure in middle age. J Natl Cancer Inst 102(21):1628–1636. https://doi.org/10.1093/jnci/djq346
Fried DV, Das SK, Marks LB (2017) Imaging radiation-induced normal tissue injury to quantify regional dose response. Semin Radiat Oncol 27(4):325–331. https://doi.org/10.1016/j.semradonc.2017.04.004 %/ Copyright (c) 2017 Elsevier Inc. All rights reserved
Robbins ME, Brunso-Bechtold JK, Peiffer AM, Tsien CI, Bailey JE, Marks LB (2012) Imaging radiation-induced normal tissue injury. Radiat Res 177(4):449–466
Warkentin M, Hopkins JB, Badeau R, Mulichak AM, Keefe LJ, Thorne RE (2013) Global radiation damage: temperature dependence, time dependence and how to outrun it. J Synchrotron Radiat 20(Pt 1):7–13. https://doi.org/10.1107/s0909049512048303
Hegemann NS, Schlesinger-Raab A, Ganswindt U, Horl C, Combs SE, Holzel D, Gschwend JE, Stief C, Belka C, Engel J (2017) Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis. Radiat Oncol 12(1):2. https://doi.org/10.1186/s13014-016-0738-z
Joung JY, Lim J, Oh CM, Jung KW, Cho H, Kim SH, Seo HK, Park WS, Chung J, Lee KH, Won YJ (2015) Risk of second primary cancer among prostate cancer patients in Korea: a population-based cohort study. PLoS One 10(10):e0140693. https://doi.org/10.1371/journal.pone.0140693
Margel D, Baniel J, Wasserberg N, Bar-Chana M, Yossepowitch O (2011) Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg 254(6):947–950. https://doi.org/10.1097/SLA.0b013e3182382fd5
Moon K, Stukenborg GJ, Keim J, Theodorescu D (2006) Cancer incidence after localized therapy for prostate cancer. Cancer 107(5):991–998. https://doi.org/10.1002/cncr.22083
Hinnen KA, Schaapveld M, van Vulpen M, Battermann JJ, van der Poel H, van Oort IM, van Roermund JG, Monninkhof EM (2011) Prostate brachytherapy and second primary cancer risk: a competitive risk analysis. J Clin Oncol 29(34):4510–4515. https://doi.org/10.1200/jco.2011.35.0991
Rapiti E, Fioretta G, Verkooijen HM, Zanetti R, Schmidlin F, Shubert H, Merglen A, Miralbell R, Bouchardy C (2008) Increased risk of colon cancer after external radiation therapy for prostate cancer. Int J Cancer 123(5):1141–1145. https://doi.org/10.1002/ijc.23601
Lehnert BE, Goodwin EH, Deshpande A (1997) Extracellular factor(s) following exposure to alpha particles can cause sister chromatid exchanges in normal human cells. Cancer Res 57(11):2164–2171
Azzam EI, de Toledo SM, Gooding T, Little JB (1998) Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of alpha particles. Radiat Res 150(5):497–504
Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J (2014) Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother Oncol 110(2):213–228. https://doi.org/10.1016/j.radonc.2013.12.012
Murray EM, Werner D, Greeff EA, Taylor DA (1999) Postradiation sarcomas: 20 cases and a literature review. Int J Radiat Oncol Biol Phys 45(4):951–961
Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, Danjoux C, Narod SA, Nam RK (2016) Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ (Clin Res Ed) 352:i851
Fan CY, Huang WY, Lin CS, Su YF, Lo CH, Tsao CC, Liu MY, Lin CL, Kao CH (2017) Risk of second primary malignancies among patients with prostate cancer: a population-based cohort study. PLoS One 12(4):e0175217. https://doi.org/10.1371/journal.pone.0175217
Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, Shariat SF, Graefen M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz PI (2010) The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys 76(2):342–348. https://doi.org/10.1016/j.ijrobp.2009.02.011
Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z (2012) Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int 110(11):1696–1701. https://doi.org/10.1111/j.1464-410X.2012.11385.x
Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll PR, Kane CJ (2007) Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 177(3):883–887; discussion 887-888. https://doi.org/10.1016/j.juro.2006.10.071
Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA (2005) Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 128(4):819–824
Berrington DGA, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E (2011) Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 12(4):353–360. https://doi.org/10.1016/S1470-2045(11)70061-4
Nieder AM, Porter MP, Soloway MS (2008) Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 180(5):2005–2009; discussion 2009-2010. https://doi.org/10.1016/j.juro.2008.07.038
Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA (2014) Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer 120(17):2735–2741. https://doi.org/10.1002/cncr.28769
Neugut AI, Ahsan H, Robinson E, Ennis RD (1997) Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 79(8):1600–1604
Van Hemelrijck M, Feller A, Garmo H, Valeri F, Korol D, Dehler S, Rohrmann S (2014) Incidence of second malignancies for prostate cancer. PLoS One 9(7):e102596. https://doi.org/10.1371/journal.pone.0102596
** T, Song T, Deng S, Wang K (2014) Radiation-induced secondary malignancy in prostate cancer: a systematic review and meta-analysis. Urol Int 93(3):279–288. https://doi.org/10.1159/000356115 %/ 2014 S. Karger AG, Basel
Muller AC, Ganswindt U, Bamberg M, Belka C (2007) Risk of second malignancies after prostate irradiation? Strahlenther Onkol 183(11):605–609. https://doi.org/10.1007/s00066-007-1786-y
Hall EJ, Wuu CS (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56(1):83–88
Bezak E, Takam R, Yeoh E, Marcu LG (2017) The risk of second primary cancers due to peripheral photon and neutron doses received during prostate cancer external beam radiation therapy. Phys Med 42:253–258. https://doi.org/10.1016/j.ejmp.2017.02.018
Murray LJ, Thompson CM, Lilley J, Cosgrove V, Franks K, Sebag-Montefiore D, Henry AM (2015) Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy. Phys Med Biol 60(3):1237–1257. https://doi.org/10.1088/0031-9155/60/3/1237
Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J (2013) Second primary cancers after radiation for prostate cancer: a review of data from planning studies. Radiat Oncol 8:172. https://doi.org/10.1186/1748-717x-8-172
Berrington de Gonzalez A, Wong J, Kleinerman R, Kim C, Morton L, Bekelman JE (2015) Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors. Int J Radiat Oncol Biol Phys 91(2):295–302. https://doi.org/10.1016/j.ijrobp.2014.10.040
Travis LB, Demark WW, Allan JM, Wood ME, Ng AK (2013) Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 10(5):289–301. https://doi.org/10.1038/nrclinonc.2013.41
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, Wiegel T, Mottet N (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642. https://doi.org/10.1016/j.eururo.2016.08.002
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003
Funding
This work was supported by the grants from National Natural Science Foundation of China (No. 81372774, No. 81572537 for Zhigang Zhao), The Key Program of Natural Science Foundation of Guangdong Province (No. 2015A030311007 for Zhigang Zhao), Yangcheng Scholar Project of Guangzhou Education Bureau (No. 12A014G for Zhigang Zhao), Science and Technology Program of Guangzhou (No. 201607010376 for Zhigang Zhao), and Science and Technology Planning Project of Guangdong Province (No.2017B030314108).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
For this type of study informed consent is not required.
Electronic supplementary material
Supplementary fig. 1
Begg’s and Egger’s tests to detect publication bias Footnotes: Rectal cancer: RT versus no-RT, 10 studies, Begg’s P > |z| = 0.152, Egger’s P > |t| = 0.634, 95%CI -3.34-2.16; RT: radiotherapy (PNG 84 kb)
Supplementary table 1
Newcastle-Ottawa Scale assessment of the quality of the cohort studies (DOC 45 kb)
Supplementary table 2
Search strategy (DOC 36 kb)
Rights and permissions
About this article
Cite this article
Zhu, Z., Zhao, S., Liu, Y. et al. Risk of secondary rectal cancer and colon cancer after radiotherapy for prostate cancer: a meta-analysis. Int J Colorectal Dis 33, 1149–1158 (2018). https://doi.org/10.1007/s00384-018-3114-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-018-3114-7